Check for updates

OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE Hongjiang Song, hongjiangsong2016@163.com Xingrui Li, lixingrui@tjh.tjmu.edu.cn

⁺These authors have contributed equally to this work

SPECIALTY SECTION This article was submitted to Predictive Toxicology, a section of the journal Frontiers in Pharmacology

RECEIVED 25 October 2022 ACCEPTED 26 October 2022 PUBLISHED 14 November 2022

CITATION

Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Song H and Li X (2022), Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/ PD-L1) outcomes. *Front. Pharmacol.* 13:1079635. doi: 10.3389/fphar.2022.1079635

COPYRIGHT

© 2022 Chen, Sun, Zhao, Huang, Pan, Zuo, Zhang, Xue, Song and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes

Li Chen **b** ^{1,2‡}, Hao Sun^{2‡}, Ruihu Zhao², Rong Huang², Hongming Pan², Yanjiao Zuo², Lele Zhang², Yingwei Xue², Hongjiang Song²* and Xingrui Li¹*

¹Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ²Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China

KEYWORDS

gastric cancer, controlling nutritional status, immune checkpoint inhibitors, PD-1, PD-L1

A Corrigendum on

Controlling nutritional status (CONUT) predicts survival ingastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1)outcomes

by Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, Zhang L, Xue Y, Li X and Song H (2022). Front. Pharmacol. 13:836958. doi: 10.3389/fphar.2022.836958

In the published article, there was an error in the **Author list** and **Correspondence** section, and authors Hongjiang Song and Xingrui Li were inserted in the wrong order. The corrected **Author list** and **Correspondence** section appear below.

"Li Chen, Hao Sun, Ruihu Zhao, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Hongjiang Song and Xingrui Li."

"*Correspondence: Hongjiang Song, hongjiangsong2016@163.com; Xingrui Li, lixingrui@ tjh.tjmu.edu.cn."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.